Top Health Tech Companies in NYC, NY (1,079)

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Profitability: Company materials describe sustained annual profitability since 2023 and cash-flow positivity, pairing growth with disciplined financial health. It also reports meeting efficiency benchmarks, noting it exceeded the Rule of 40 in 2025.

Strong Revenue Growth: Disclosures point to multi-year revenue expansion with momentum described as accelerating, indicating robust top-line performance. This growth is presented alongside expanding provider and patient scale.

Strategic Partnerships: The platform is increasingly embedded across external channels through integrations with Healthgrades, Yelp, Google Gemini, and payer portals, broadening distribution and demand capture. These arrangements signal deeper ecosystem reach beyond the core marketplace.

Market Expansion: National and payer footprint have broadened materially, with availability across all 50 states, plan relationships rising toward 100+, and sharp increases in providers, patients, and appointments. This widening reach indicates an ability to capture demand across geographies and insurance lines.

Investor Backing & Capital Strength: A $100M Series D at a roughly $2.3B valuation alongside substantial prior financing reflects strong access to growth capital. This position supports continued scaling of the network, product investments, and deeper insurer integrations.

Strong Revenue Growth: Revenue is described as having increased significantly over a recent 12‑month period, with earlier disclosures citing outsized year‑over‑year gains. Coupled with rising session volumes, this points to robust top‑line momentum despite limited public financial detail.

Strong Revenue Growth: Available disclosures indicate revenue grew at a triple‑digit rate year over year in early 2026 and was later described as roughly $200M after multiple years of doubling. These signals point to rapid scaling beyond a purely funding‑led story.

Investor Backing & Capital Strength: Back‑to‑back late‑stage rounds in 2026, including a nine‑figure Series D followed quickly by a nine‑figure Series E with a stepped‑up valuation, suggest deep capital access and investor conviction. The rapid valuation increase provides additional financial flexibility for expansion.

Strategic Partnerships: Announcements in 2026 with organizations such as Atlantic Health and Priority Health indicate expanding distribution channels beyond direct employer sales. These relationships broaden market reach and embed the offering within health systems and plans.

Market Expansion: The platform’s footprint expanded from 400 participating sites in 2022 to 6,000+ sites by 2026, with presence across 50+ countries and 25+ sponsors. Evidence indicates marketplace adoption more than doubled in 2023 and activity surpassed 100 trials by 2024.

Product Line Growth: The offering broadened from a marketplace into AI-powered patient pre-screening and integrated workflows, with reported operational time savings and enrollment improvements in case studies. Subsequent integrations with CRIO, RealTime eClinical, and eClinPro signal continued platform expansion.

Strategic Partnerships: Relationships include major pharmaceutical organizations (e.g., 16 of the top 30 in 2024 and now 25+ sponsors) and ecosystem deals such as RealTime eClinical (50+ networks representing 2,000+ sites) plus CRIO/eClinPro integrations. These ties appear to extend distribution and enrich data used for site selection and enrollment.

Strong Revenue Growth: Inc.’s 2026 profile cites exceptional multi-year growth and nine-figure 2025 revenue, signaling unusually fast top-line expansion with third-party validation of the inputs it used. Operating milestones such as surging patient volume and completed appointments align with a company moving from early-stage to substantial scale.

Investor Backing & Capital Strength: Late-stage financings—$70M in 2025 and $100M in 2026—brought total funding to $215M, indicating deep capital access and sustained investor confidence. Reported unicorn-level valuations further underscore the ability to secure significant backing for continued expansion.

Strong Market Position & Advantage: Scale signals including a 10,000+ dietitian network, hundreds of thousands of patients served, nationwide availability, and broad payer reach depict a leading position in dietitian-led virtual nutrition care. Industry recognition (e.g., Inc. 5000 placement and Fierce 15 mentions) adds to perceived competitive advantage.

Strong Revenue Growth: Repeated inclusion on the Inc. 5000 list and an Inc. profile noting 27% three-year growth for 2026 indicate sustained top-line expansion.

Market Expansion: Acquisitions in 2023 (ABA Therapy Billing & Insurance Services) and 2025 (Joshin), plus the addition of a Chief Revenue Officer and an SVP of Enterprise Sales, point to expansion across providers, disability support, and enterprise channels.

Innovation-Driven Growth: New AI-enabled capabilities for behavioral-health workflows and analytics recognition suggest product momentum that supports continued scaling.

Strong Revenue Growth: Estimates indicate annualized revenue rose sharply in 2024, with acceleration tied to GLP-1/obesity care. Evidence cites roughly $598M annualized revenue in 2024 versus about $360M in 2023.

Market Expansion: Recent launches and channel moves broadened reach, including nationwide availability of the Wegovy pill and a surge of new customers in early 2026. The platform reports helping millions of patients across nearly every U.S. county.

Strategic Partnerships: Direct integrations with major manufacturers (e.g., Novo Nordisk’s NovoCare for Wegovy and additional GLP-1 collaborations) position the company as a distribution/access channel. Novo Nordisk specifically described the company as part of its direct-to-patient expansion.

Investor Backing & Capital Strength: Recent financings include a $55M Series B led by Insight Partners and a prior $15M Series A, bringing total reported funding to roughly $77M. These capital events coincide with visible signals like active hiring and continued platform build-out.

Strong Revenue Growth: Growth is repeatedly described as 5x year-over-year since the Series A, alongside a 5x increase in valuation. Customer adoption reportedly expanded to 250+ CPG brands with $30B+ in retail sales planning flowing through the platform.

Product Line Growth: The offering has broadened from cash application and deductions into trade promotion management, sales forecasting, demand/supply planning, and analytics. Additions such as AI contract reading, auto‑disputes, and the Muffin Data acquisition indicate ongoing capability expansion.

Market Expansion: Adoption appears to have increased from 19,000+ hospitals in June 2023 to 23,000+ currently, indicating continued penetration of the U.S. veterinary market. The platform is also described as powering purchasing infrastructure for the majority of several practice types nationwide.

Product Line Growth: The offering has expanded from a price-comparison tool into a broader procurement ecosystem spanning distributors, manufacturers, and diagnostic labs, with a catalog covering 99.9% of products veterinarians use. This evolution points to a shift toward comprehensive procurement infrastructure rather than a single-point solution.

Strong Market Position & Advantage: A 23,000+ hospital installed base and a supplier-side marketplace marketed as access to 23,000+ clinics suggest reinforcing network effects. Monetization on the supplier/manufacturer side and corporate capabilities further underscore centrality in the purchasing workflow.

Market Expansion: International footprint is described as rapidly scaling, with the oncology research network tripling year over year and later noted as nearly 70% ex‑U.S. growth across the UK, Germany, Japan, and new regions like Scotland. Point‑of‑care reach is also portrayed as expanding, with 1,600+ sites of care and increases from earlier baselines.

Product Line Growth: New offerings include the launch of Flatiron Telescope and multiple AI-enabled datasets, alongside expansions of major assets such as the NSCLC Panoramic dataset. Additional capabilities like LLM-based data extraction and new hematology datasets indicate broader, monetizable product breadth.

Strategic Partnerships: Collaborations are highlighted with organizations such as NCCN, Quest Diagnostics, Candid Health, TailorMed, and DeepScribe, as well as a multi‑year partnership alongside the Paradigm transaction. Engagements with 20+ global oncology drug developers and academic institutions reinforce a partnership‑driven operating model.

Strong Revenue Growth: Operating revenue increased meaningfully year over year while capacity also rose, signaling robust top-line momentum in tandem with expanding operations. Feedback suggests this growth has been sustained across consecutive fiscal periods.

Market Expansion: The network has broadened to 32 destinations with cumulative passengers surpassing 25 million, alongside added international routes and higher departures. These developments indicate widening reach and growing traffic throughput.

Future-Ready Strategy: Management outlines continued capacity growth over the next several years, supported by a large Boeing 737 MAX order pipeline. This long-horizon fleet plan underpins ongoing scale-up ambitions.

Investor Backing & Capital Strength: Capital raised expanded meaningfully, including a $30M Series A in 2022 led by Optum Ventures with participation from Cigna Ventures, bringing total funding to about $40M. This capital base is presented as enabling expansion and signals strong support from prominent healthcare investors.

Product Line Growth: The company broadened from health‑plan administration to a healthcare‑data infrastructure platform with integrations, analytics, actuarial tools, and AI agents. Launches and deployments such as PBM connections and multiple vendor integrations indicate a widening offering and use cases.

Innovation-Driven Growth: Positioning centers on an integration platform for the payer ecosystem with elements like canonical data models, knowledge graphs, and agentic analytics, reflecting ongoing innovation. Evolving documentation and case activity reinforce a trajectory of product advancement rather than a static portfolio.

Product Line Growth: Growth across non‑COVID medicines such as Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec/Vydura and oncology biosimilars has been robust. Launched and acquired products are showing sustained double‑digit operational gains, adding meaningful momentum.

Resilient & Sustainable Growth: Excluding COVID products, the underlying portfolio delivered mid‑single‑digit operational growth in 2025 and continued at a similar pace in early 2026, more than offsetting part of the COVID‑related decline. Reported revenue also returned to modest year‑over‑year growth in the first half of 2026, indicating stabilization.

Future-Ready Strategy: Management raised the midpoint of 2026 revenue guidance and continues to invest heavily in a broad late‑stage pipeline. This posture signals confidence that newer launches and acquired assets can drive the next leg of growth.

Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.

Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.

Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.

Market Expansion: Granted is extending beyond direct-to-consumer into institutional channels, launching a North Texas educator program initially covering 5,000+ Mesquite ISD employees with additional districts expected. A September 2026 rollout of Clear the Bill further signals targeted regional program expansion.

Strategic Partnerships: Collaborations with First Financial Group of America and StretchDollar are broadening access through employer and benefits distribution. These partnerships are described as recent commercial expansions and the company’s first school‑district collaboration.

Investor Backing & Capital Strength: The company secured approximately $16.25M–$16.3M in a 2024 Series A/financing, cited by multiple industry sources. This level of backing indicates meaningful investor support for continued development and scaling.

Investor Backing & Capital Strength: Evidence indicates a $55M Series B in 2026 brought cumulative funding above $73M to accelerate hiring, R&D, and platform adoption. This capital position supports scaling operations and product development.

Strong Revenue Growth: Company materials state revenue increased 4× in the 12 months prior to April 2024, with earlier periods citing 24× growth and expectations to more than double in 2022. These signals indicate rapid top-line expansion, though current figures are not independently audited.

Product Line Growth: The offering has expanded beyond payment integrity into utilization management and appeals while launching AI agents for DRG validation, readmissions, and emergency-department reviews. This broadening scope increases relevance across health‑plan claims workflows.

Product Line Growth: Newer businesses such as Pharma Direct and subscriptions are expanding rapidly, with clear momentum highlighted in 2026. Investment is being shifted toward these lines to replace slower legacy revenue.

Future-Ready Strategy: Management is prioritizing Pharma Direct and subscription products and raised 2026 revenue guidance, signaling a transition aimed at restoring overall growth. These segments are described as the main engines expected to offset declines in the legacy business.

Profitability: Profitability remains solid even as the top line fluctuates, including positive GAAP earnings and substantial adjusted EBITDA in Q2 2026. Operating cash flow also strengthened, supporting continued execution.

Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.

Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.

Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.

Strong Revenue Growth: Top-line revenue is reported to have grown strongly on a multi-year basis through 2023, with additional indications of continued increases into 2025–2026. This provides the clearest quantitative signal of momentum for a private company with limited disclosures.

Market Expansion: The provider network and product footprint have broadened, including new launches such as programmatic access and a consumer health media offering alongside partnerships that extend reach. These moves show growth beyond core point-of-care screens into adjacent adtech and consumer channels.

Investor Backing & Capital Strength: Advent International’s 2025 agreement to acquire the company and continued investment signal substantial sponsor support for scaling. Such backing typically underwrites further network growth and product innovation.